LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) saw a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 25,100 shares, a decrease of 17.2% from the January 31st total of 30,300 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 435,300 shares, the short-interest ratio is currently 0.1 days.

LAVA Therapeutics Price Performance

Shares of LAVA Therapeutics stock traded up $0.04 on Wednesday, hitting $1.32. 151,643 shares of the company’s stock traded hands, compared to its average volume of 591,244. LAVA Therapeutics has a one year low of $0.85 and a one year high of $4.21. The stock has a market capitalization of $34.70 million, a PE ratio of -1.28 and a beta of 0.57. The firm’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.42.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings data on Tuesday, December 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.11). On average, analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Finally, HC Wainwright reissued a “neutral” rating and issued a $1.50 target price (down from $2.00) on shares of LAVA Therapeutics in a research note on Thursday, February 27th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.17.

Institutional Trading of LAVA Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Sanofi acquired a new stake in shares of LAVA Therapeutics during the fourth quarter worth about $1,825,000. BNP Paribas Financial Markets bought a new position in LAVA Therapeutics in the fourth quarter valued at approximately $40,000. Finally, Virtu Financial LLC acquired a new position in shares of LAVA Therapeutics in the third quarter valued at approximately $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.